Aileron Therapeutics, Inc.

Aileron Therapeutics, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Aileron Therapeutics, Inc. has good growth characteristics. Aileron Therapeutics, Inc. is a mediocre stock to choose.
Log in to see more information.
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on developin...

News

Aileron Therapeutics to Present at the 8th Annual IPF Summit
Aileron Therapeutics to Present at the 8th Annual IPF Summit

PR Newswire Aileron Therapeutics to Present at the 8th Annual IPF Summit Aileron Therapeutics to Present at the 8th Annual IPF Summit PR Newswire AUSTIN, Texas, Aug. 19, 2024 AUSTIN, Texas, Aug. 19, 2024...\n more…

Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Declines By 12.8%
Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Declines By 12.8%

Ticker Report Aileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) was the recipient of a large decrease in short interest during the month of July. As of July 31st, there was short interest totalling...\n more…

FY2024 Earnings Forecast for Aileron Therapeutics, Inc. (NASDAQ:ALRN) Issued By Brookline Capital Management
FY2024 Earnings Forecast for Aileron Therapeutics, Inc. (NASDAQ:ALRN) Issued By Brookline Capital Management

Ticker Report Aileron Therapeutics, Inc. (NASDAQ:ALRN - Free Report) - Stock analysts at Brookline Capital Management decreased their FY2024 earnings estimates for Aileron Therapeutics in a report released on...\n more…

Aileron Therapeutics (NASDAQ:ALRN) Issues Quarterly  Earnings Results, Misses Estimates By $0.20 EPS
Aileron Therapeutics (NASDAQ:ALRN) Issues Quarterly Earnings Results, Misses Estimates By $0.20 EPS

Zolmax Aileron Therapeutics (NASDAQ:ALRN - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.25) by...\n more…

ALRN Stock Earnings: Aileron Therapeutics Misses EPS for Q2 2024
ALRN Stock Earnings: Aileron Therapeutics Misses EPS for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nALRN stock results show that Aileron Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.\nThe post...\n more…

Aileron Therapeutics reports Q2 EPS (45c), one estimate (42c)
Aileron Therapeutics reports Q2 EPS (45c), one estimate (42c)

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…